Icon Advisers Inc. Co. Invests $1,637,000 in Steris Corp. (STE)
Icon Advisers Inc. Co. bought a new position in shares of Steris Corp. (NYSE:STE) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 22,400 shares of the company’s stock, valued at approximately $1,637,000.
A number of other large investors also recently added to or reduced their stakes in STE. Janus Capital Management LLC increased its stake in Steris Corp. by 28.7% in the second quarter. Janus Capital Management LLC now owns 5,022,412 shares of the company’s stock worth $345,288,000 after buying an additional 1,120,438 shares during the last quarter. Wells Fargo & Company MN increased its stake in Steris Corp. by 10.3% in the third quarter. Wells Fargo & Company MN now owns 3,271,198 shares of the company’s stock worth $239,125,000 after buying an additional 306,064 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in Steris Corp. by 2.2% in the second quarter. Westfield Capital Management Co. LP now owns 3,035,201 shares of the company’s stock worth $208,670,000 after buying an additional 64,702 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in Steris Corp. by 7.0% in the second quarter. Massachusetts Financial Services Co. MA now owns 1,963,285 shares of the company’s stock worth $134,975,000 after buying an additional 128,956 shares during the last quarter. Finally, Fisher Asset Management LLC increased its stake in Steris Corp. by 1.0% in the third quarter. Fisher Asset Management LLC now owns 1,639,312 shares of the company’s stock worth $119,834,000 after buying an additional 16,808 shares during the last quarter. Hedge funds and other institutional investors own 91.99% of the company’s stock.
Steris Corp. (NYSE:STE) traded down 1.91% during midday trading on Wednesday, reaching $65.61. 450,284 shares of the company’s stock traded hands. Steris Corp. has a 52 week low of $61.38 and a 52 week high of $78.77. The company’s 50-day moving average price is $67.22 and its 200 day moving average price is $69.39. The stock has a market capitalization of $5.59 billion, a price-to-earnings ratio of 33.12 and a beta of 1.30.
Steris Corp. (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by $0.01. Steris Corp. had a net margin of 6.41% and a return on equity of 9.89%. The firm had revenue of $646.40 million for the quarter, compared to analysts’ expectations of $670.24 million. During the same period in the prior year, the company posted $0.83 earnings per share. Steris Corp.’s quarterly revenue was up 31.9% compared to the same quarter last year. On average, equities research analysts expect that Steris Corp. will post $3.90 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 21st. Shareholders of record on Wednesday, November 23rd will be paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 1.71%. The ex-dividend date is Monday, November 21st. Steris Corp.’s dividend payout ratio is presently 57.14%.
STE has been the subject of a number of recent analyst reports. JMP Securities restated a “buy” rating on shares of Steris Corp. in a report on Friday, November 4th. Zacks Investment Research downgraded shares of Steris Corp. from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. Finally, Goldman Sachs Group Inc. initiated coverage on shares of Steris Corp. in a research note on Wednesday. They set a “neutral” rating and a $71.00 price objective for the company.
In other news, VP John Adam Zangerle sold 2,200 shares of the stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $67.00, for a total value of $147,400.00. Following the completion of the sale, the vice president now directly owns 26,166 shares of the company’s stock, valued at $1,753,122. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard Martin Steeves sold 204,778 shares of the stock in a transaction that occurred on Wednesday, September 7th. The stock was sold at an average price of $71.19, for a total transaction of $14,578,145.82. Following the completion of the sale, the director now directly owns 165,434 shares of the company’s stock, valued at $11,777,246.46. The disclosure for this sale can be found here. Company insiders own 2.52% of the company’s stock.
Steris Corp. Company Profile
STERIS Corporation (STERIS) is a provider of infection prevention and other procedural products and services. The Company is focused on healthcare, pharmaceutical and research. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The Healthcare segment provides surgical, sterile processing, infection prevention and gastrointestinal solutions.
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Steris Corp. (NYSE:STE).
Receive News & Ratings for Steris Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Corp. and related companies with MarketBeat.com's FREE daily email newsletter.